BIAF News & Events

bioAffinity Technologies announced continued acceleration in commercial sales for CyPath Lung, its noninvasive lung cancer diagnostic, with more than 200% growth year-over-year. The number of tests sold in Q2 2026 represents an increase of more than 30% over Q1 2026 and more than 200% compared with Q2 2025. The company has now performed nearly 3,000 CyPath Lung tests since commercial launch, reflecting growing physician adoption. bioAffinity Technologies is advancing multiple initiatives that the company believes will further expand the clinical impact of its proprietary technology platform. These include a large-scale longitudinal clinical study designed to generate additional validation data for CyPath Lung, expansion into oncology by using CyPath Lung to monitor lung cancer survivors after treatment, and an R&D pipeline that includes diagnostic tests for asthma and COPD that are designed to help guide personalized treatment with targeted therapies.

bioAffinity Technologies will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs that kill squamous and basal skin cancer cells in vitro while leaving non-cancerous skin cells unharmed. The newly released findings support the Company's efforts to develop topical treatments for squamous cell and basal cell carcinoma, two of the most common forms of skin cancer. "Our preclinical results represent an encouraging step toward developing less-invasive treatments for some of the most common cancers affecting patients today," said Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer. "This research reinforces our innovative approach to cancer treatments and expands our mission to improve cancer outcomes by developing technologies designed to detect and treat cancer earlier and more precisely."

bioAffinity Technologies priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2M, before deducting agent fees and other estimated expenses payable by the company. The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share at a purchase price of $0.80 per share. Each pre-funded warrant will be exercisable for one share of common stock and will be immediately exercisable and will expire when exercised in full. The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions. WallachBeth Capital is acting as sole placement agent for the offering.